Stevanato Group S.p.A. (NYSE:STVN) Shares Sold by Northern Trust Corp

Northern Trust Corp cut its holdings in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 55.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,887 shares of the company's stock after selling 94,812 shares during the period. Northern Trust Corp's holdings in Stevanato Group were worth $1,632,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. M&T Bank Corp purchased a new position in Stevanato Group in the 4th quarter valued at about $572,000. Mutual of America Capital Management LLC purchased a new position in Stevanato Group in the 4th quarter valued at about $13,848,000. Advantage Alpha Capital Partners LP lifted its holdings in Stevanato Group by 27.3% in the 4th quarter. Advantage Alpha Capital Partners LP now owns 293,865 shares of the company's stock valued at $6,403,000 after purchasing an additional 63,041 shares in the last quarter. Allianz SE purchased a new position in Stevanato Group in the 4th quarter valued at about $748,000. Finally, Zions Bancorporation N.A. lifted its holdings in Stevanato Group by 29.7% in the 4th quarter. Zions Bancorporation N.A. now owns 68,017 shares of the company's stock valued at $1,482,000 after purchasing an additional 15,555 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on STVN shares. UBS Group reduced their target price on shares of Stevanato Group from $24.00 to $23.50 and set a "neutral" rating on the stock in a report on Friday, March 7th. Stephens raised shares of Stevanato Group to a "strong-buy" rating in a research note on Monday, April 21st. Finally, William Blair reaffirmed an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of €25.70 ($29.20).

Stevanato Group Trading Down 3.6%

STVN traded down €0.83 ($0.94) on Friday, reaching €22.05 ($25.06). 200,500 shares of the company's stock were exchanged, compared to its average volume of 338,130. The company's 50 day moving average is €21.79 and its 200-day moving average is €21.35. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 46.91, a PEG ratio of 7.18 and a beta of 0.51. Stevanato Group S.p.A. has a twelve month low of €16.56 ($18.82) and a twelve month high of €25.75 ($29.26). The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last posted its earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of €0.20 ($0.23). The firm had revenue of €352.68 million during the quarter, compared to the consensus estimate of €346.26 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. Equities analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Stevanato Group Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be given a dividend of $0.0613 per share. This represents a yield of 0.3%. The ex-dividend date is Thursday, June 5th. This is an increase from Stevanato Group's previous annual dividend of $0.05. Stevanato Group's dividend payout ratio is 11.76%.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.